Prognostic analysis of children with Henoch-Schonlein purpura treated by Helicobacter pylori eradication therapy.
- Author:
Hua-Bo CAI
1
;
Yong-Bai LI
;
Hui ZHAO
;
Shao-Ming ZHOU
;
Xiao-Dong ZHAO
Author Information
- Publication Type:Journal Article
- MeSH: Child; Child, Preschool; Female; Helicobacter Infections; complications; drug therapy; Helicobacter pylori; Humans; Incidence; Male; Prognosis; Purpura, Schoenlein-Henoch; epidemiology; etiology; Recurrence
- From: Chinese Journal of Contemporary Pediatrics 2014;16(3):234-237
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effect of Helicobacter pylori (Hp) eradication therapy on prognosis in children with Henoch-Schonlein purpura (HSP).
METHODSA total of 153 children with HSP were divided into Hp infection treatment group (n=22), Hp infection control group (n=21), and Hp infection-negative group (n=110). The Hp infection treatment group received one-week triple therapy for Hp eradication in addition to conventional treatment, while the Hp infection control group and Hp infection-negative group received conventional treatment. All patients were followed up for prognostic evaluation.
RESULTSThe response rates of the Hp infection treatment, control, and negative groups were 86% (19/22), 90% (19/21) and 85% (94/110), respectively (P>0.05). The recurrence rates of HSP in the Hp infection treatment, control, and negative groups were 14% (3/22), 24% (5/21) and 31% (34/110), respectively (P>0.05). The incidence of Henoch-Schonlein purpura nephritis (HSPN) in the Hp infection-negative group (36%, 40/110) and control group (33%, 7/21) was significantly higher than that in the Hp infection treatment group (5%, 1/22) (P<0.05 for both), but no significant difference in the incidence of HSPN was found between the control and negative groups (P>0.05).
CONCLUSIONSOne-week triple therapy for Hp eradication may be useful to reduce the incidence of HSPN in children with HSP infected with Hp.
